Hints and tips:
Related Special Reports
...Janssen is the pharmaceutical division of J&J....
...Not only was the BioNTech/Pfizer vaccine the first to be deployed but it has suffered less from rare side effects and manufacturing glitches than its big western rivals Oxford/AstraZeneca, Janssen or Moderna...
...A booster shot of Johnson & Johnson’s Covid-19 vaccine produced a strong and rapid antibody response against the virus, the pharmaceutical company said on Wednesday....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...“The Janssen vaccine will be another weapon in our arsenal to beat this pandemic,” said vaccines minister Nadhim Zahawi....
FDA will now weigh whether to allow use of first single-dose jab to prevent the virus
..., J&J’s pharmaceutical division, told the panel on Friday: “Janssen’s vaccine candidate would play a critical role in the global efforts to fight Covid-19 . . ....
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
...“At present, no clear causal relationship has been established between these rare events and the Janssen [J&J] Covid-19 vaccine,” it said, adding that it was working closely with experts and regulators to...
...J&J is preparing to test a new formulation that could be targeted at the 501.v2 variant, but Mathai Mammen, global head of research and development for Janssen, J&J’s pharmaceuticals division, said he was...
...“The acquisition was driven by the significant opportunity seen in nipocalimab, along with the scientific capability Janssen is acquiring with the Momenta team,” J&J said in a statement....
...Through its Janssen subsidiary, the New Jersey-based drugmaker will administer its experimental vaccine to 6,000 UK volunteers in two doses in a phase-3 trial....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
...He joined Janssen, J&J’s pharma division, in sales in 1988, with only a BA in biology....
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
...J&J — best known for consumer products such as “no more tears” baby shampoo — owns the Janssen pharmaceuticals business that sold two prescription opioids....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...Allergan, a Dublin-based pharmaceuticals company, is developing another antidepressant based on the glutamate system. It hopes to announce the results of its phase-3 clinical study on Rapastinel soon....
...Mr Rouse acknowledges that, Janssen’s enthusiasm aside, other companies have been less convinced of the advantages of outcomes-based pricing....
...She worked as a janitorial supervisor at C&W client Lonza, a Swiss pharmaceuticals group, which has a production facility in Portsmouth, New Hampshire....
...Two leading pharmaceutical companies have warned that the UK must continue to attract top scientific talent if it is to maintain its competitive edge....
...He places human embryonic and pluripotent stem cells — that have the potential to grow into nearly every cell of the body — in tiny ‘U’ or ‘V’ shaped dishes in the lab to grow them into different types of...
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
International Edition